Risks of mifepristone abortion in context.
نویسنده
چکیده
Media attention concerning the recent update to the mifepristone labeling by the US Food and Drug Administration and Danco Laboratories has led to misconceptions about the safety of medical abortion [1]. Three women in the United States have died related to medical abortion with mifepristone (one from a ruptured ectopic pregnancy and two from infection). Approximately 360,000 women have used the drug for this procedure (personal communication, Danco Laboratories, November 18, 2004). Hence, the estimated case-fatality rate for mifepristone abortion is 0.8 deaths per 100,000 procedures (95% confidence interval, 0.2–2.4 by Poisson distribution). This risk is statistically indistinguishable from the risk of death from spontaneous abortion (0.7 per 100,000 miscarriages) [2]. The risk is also comparable to that associated with induced abortion overall (mostly surgical procedures) (0.7 deaths per 100,000 procedures) [3]. The risk of death from either spontaneous or induced abortion, including mifepristone medical abortion, is much lower than that associated with childbirth. In 1997, the pregnancy-related mortality ratio was 12.9 deaths per 100,000 live births [4]. Even in women who are not pregnant, infection of the upper genital tract carries a risk of death [5]. Not all such infections are related to sexually transmitted pathogens; the normal flora of the lower genital tract may be implicated. For example, in married women with only one sexual partner, frequent coitus (defined as six or more episodes per week) is associated with a threefold increased risk of upper genital tract infection compared with coitus less than once per week [6]. In summary, the risk of death associated with medical abortion is remote and virtually identical to that with spontaneous and surgical abortion. These risks are substantially less than the risk of continuing the pregnancy. Septic abortion deaths reveal a common theme: delay in recognizing illness, delay in getting medical help, and delay in beginning treatment [7].
منابع مشابه
Different Time Schedules of Mifepristone and Misoprostol in Second Trimester Medical Abortion: A Comparative Study
Background & aim: Recently, the use of mifepristone followed by misoprostol after 36-48 h has been demonstrated to be an effective and safe method for the second trimester medical abortion. However, this regimen entails long total abortion time, and consequently increases the financial burden and anxiety in the patients. We hypothesize that one day interval would be also effective and can be us...
متن کاملHaving an abortion using mifepristone and home misoprostol: a qualitative analysis of women's experiences.
CONTEXT Women choose medical over surgical abortion because it is more natural, more private and less painful. Whether their perceptions change during the medical abortion process has not been explored. METHODS A nonprobabilitysample of 43 participants in a clinical trial of abortion using mifepristone completed two open-ended questionnaires about this method, one before taking mifepristone a...
متن کاملMifepristone in South Australia -- the first 1343 tablets.
BACKGROUND Mifepristone has recently become available in Australia but its use is restricted. OBJECTIVE To describe the use of mifepristone in South Australia in the period 2009-2010 and to explore options that may become available to general practitioners. DISCUSSION Mifepristone has been added to regimens for early and second trimester abortions - both medical and surgical abortions. It h...
متن کاملMifepristone-induced early abortion and outcome of subsequent wanted pregnancy.
Follow-up information on subsequent pregnancies after mifepristone (RU486)-induced abortion is scarce. The authors examined whether one mifepristone-induced first-trimester abortion affects the outcome of a subsequent wanted pregnancy. In a study conducted in 1998-2001 at antenatal clinics in Beijing, Chengdu, and Shanghai, China, the authors enrolled 4,925 women with no history of induced abor...
متن کاملNormalizing the exceptional: incorporating the "abortion pill" into mainstream medicine.
Mifepristone, also known as RU-486, and in the US known as "the French abortion pill", finally received FDA approval in the United States in September 2000. This paper discusses the steps now in process to integrate this drug into mainstream healthcare and the sociological implications of those efforts. Each of the steps that is normally taken to introduce a newly approved medication in the US ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Contraception
دوره 72 5 شماره
صفحات -
تاریخ انتشار 2005